Table 5.

League table presenting the NMA results of adverse effects.

Risankizumab 360 mg	.	.	1.17 [0.74; 1.84]	.	.	.	1.37 [0.84; 2.22]	.	.	.	.
1.03 [0.55; 1.93]	Guselkumab 1200 mg IV, then 200 mg sc	1.09 [0.76; 1.56]	.	.	.	.	1.32 [0.89; 1.96]	.	.	.	.
1.12 [0.60; 2.11]	1.09 [0.76; 1.56]	Guselkumab 200 mg sc	.	.	.	.	1.22 [0.81; 1.83]	.	.	.	.
1.17 [0.74; 1.84]	1.13 [0.59; 2.15]	1.04 [0.54; 1.99]	Risankizumab 180 mg	.	.	.	1.17 [0.71; 1.94]	.	.	.	.
1.32 [0.77; 2.25]	1.28 [0.81; 2.02]	1.18 [0.73; 1.88]	1.13 [0.65; 1.97]	CJM112	.	.	1.04 [0.82; 1.31]	.	.	.	.
1.33 [0.75; 2.34]	1.28 [0.78; 2.11]	1.18 [0.71; 1.97]	1.14 [0.63; 2.05]	1.01 [0.69; 1.47]	Bimekizumab	.	1.12 [0.76; 1.67]	0.97 [0.69; 1.37]	.	.	.
1.36 [0.83; 2.25]	1.32 [0.87; 2.00]	1.22 [0.79; 1.87]	1.17 [0.69; 1.97]	1.04 [0.79; 1.35]	1.03 [0.74; 1.43]	Secukinumab q2w	1.00 [0.88; 1.13]	.	1.01 [0.89; 1.15]	.	.
1.37 [0.84; 2.22]	1.32 [0.89; 1.96]	1.22 [0.81; 1.83]	1.17 [0.71; 1.94]	1.04 [0.82; 1.31]	1.03 [0.76; 1.39]	1.00 [0.88; 1.13]	Placebo	1.00 [0.90; 1.11]	1.01 [0.89; 1.14]	1.14 [0.89; 1.47]	1.20 [0.85; 1.71]
1.37 [0.83; 2.24]	1.32 [0.88; 1.99]	1.22 [0.80; 1.86]	1.17 [0.70; 1.97]	1.04 [0.80; 1.34]	1.03 [0.77; 1.39]	1.00 [0.85; 1.18]	1.00 [0.90; 1.11]	Adalimumab	.	.	.
1.38 [0.84; 2.27]	1.33 [0.88; 2.02]	1.23 [0.80; 1.89]	1.18 [0.70; 1.99]	1.05 [0.80; 1.36]	1.04 [0.75; 1.44]	1.01 [0.89; 1.15]	1.01 [0.89; 1.14]	1.01 [0.86; 1.19]	Secukinumab q4w	.	.
1.56 [0.91; 2.69]	1.51 [0.95; 2.41]	1.39 [0.86; 2.25]	1.34 [0.76; 2.35]	1.18 [0.84; 1.67]	1.18 [0.80; 1.74]	1.14 [0.87; 1.51]	1.14 [0.89; 1.47]	1.14 [0.87; 1.50]	1.13 [0.86; 1.50]	Avacopan	.
1.65 [0.91; 2.99]	1.59 [0.94; 2.70]	1.47 [0.86; 2.51]	1.41 [0.76; 2.61]	1.25 [0.82; 1.90]	1.24 [0.78; 1.97]	1.21 [0.83; 1.75]	1.20 [0.85; 1.71]	1.20 [0.83; 1.73]	1.19 [0.82; 1.73]	1.05 [0.69; 1.62]	IFX-1 800 mg Q4w